CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

GimsilumabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug474 Lopinavir 200Mg/Ritonavir 50Mg Tab Wiki 1.00
drug82 Azithromycin Wiki 0.21
drug360 Hydroxychloroquine Wiki 0.13
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.32
D055371 Acute Lung Injury NIH 0.16
D013577 Syndrome NIH 0.15
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.

Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.

NCT04351243 Respiratory Distress Syndrome Due to COVID-19 Drug: Gimsilumab Drug: Placebo
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Lung Injury Syndrome

Primary Outcomes

Description: Vital status at Day 43

Measure: Primary endpoint

Time: 43 days

Secondary Outcomes

Description: Incidence and duration of mechanical ventilation use during the study

Measure: Secondary endpoint

Time: Day 43

Description: Number of days in the ICU

Measure: Secondary endpoint

Time: Day 43

Description: Number of days of inpatient hospitalization

Measure: Secondary endpoint

Time: Day 43

No related HPO nodes (Using clinical trials)